(Lymphoma) Ezharmia Launched for Sale in Japan
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
- December 23, 2022
- Read time: 1 minute
On December 20, 2022, Daiichi Sankyo Co., Ltd. announced the launch of Ezharmia, a treatment drug for relapsed or refractory adult T-cell leukemia-lymphoma (ATL), available in 50 mg and 100 mg tablet formulations.
Adult T-cell leukemia-lymphoma is one of the common hematological malignancies in Japan, with approximately 1,000 new cases detected annually. It is known that ATL is caused by HTLV-1 infection, but no effective method or treatment to prevent its onset has been found.
This launch was based on results from a Phase II clinical trial conducted in Japan, enrolling relapsed or refractory ATL patients (N=25) treated with Ezharmia to evaluate safety and efficacy. The primary endpoint response rate was 48%, comprising 5 patients with complete remission, 37 patients with partial remission, and 10 patients with stable disease.
Additionally, based on the trial results, Ezalmia received designation as an orphan drug by the Ministry of Health, Labour and Welfare in November 2021 and received domestic manufacturing and marketing approval in Japan in September 2022.
Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202212/20221220_J.pdf
- Clinical Trial Medications
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4